Sign In
CPSI Share                                                                      


Viral respiratory infections (VRI) cause increased morbidity and mortality in both adult and pediatric healthcare settings. Age is a key risk factor with regards to the severity, transmission and impact of VRI. The consequences of VRI are especially concerning for children and older adults with existing co-morbidities or underlying conditions such as cardiac and pulmonary disease, or immunosuppression. The emergence of SARS, avian influenza, novel H1N1 influenza, MERS-CoV and, recently, COVID-19 have underlined the need for data to inform infection prevention and control practices for respiratory pathogens in healthcare settings.


A hospital’s ability to appropriately manage COVID-19 and other VRI patients will be dependent on their understanding of the burden of both community and healthcare associated severe respiratory infections. This surveillance will assist in understanding the burden of COVID-19 and other VRI in adults and pediatric patients in Canadian hospitals.
A real-time hospital based surveillance system will assist in identifying high-risk groups, as well as describing risk factors and patient outcomes in order to inform public health decisions and evaluate interventions.

Short term objectives

  1. Describe the inpatient population infected with COVID-19
  2. Provide timely data (e.g. demographic, clinical and outcome data) to hospitals and PHAC regarding patients hospitalized with COVID-19

Long term objectives

  1. Identify new and emerging respiratory viruses in Canadian acute care hospitals 

  2. Describe risk factors and outcomes of the pediatric and adult populations who develop VRI in order to inform infection prevention and control strategies  

  3. Facilitate intra- and inter-hospital comparison of adult and pediatric VRI rates over time 

  4. Describe nosocomial transmission of COVID-19 in acute care hospitals 

  5. Compare the epidemiology of COVID-19 infection to other viral respiratory infections (e.g. influenza and RSV) among pediatric and adult inpatients  

  6. Measure the impact of COVID-19 on antimicrobial utilization and antimicrobial resistance